Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Big Sky, Montana
March 17 2023 - 10:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the “Company” or
“PetVivo") an emerging biomedical device company focused on the
commercialization of innovative medical devices and therapeutics
for companion animals announced that Erik Kleemam DVM, MPH, of
Ethos Veterinary Health presented at the Veterinary Orthopedic
Society (“VOS”) annual conference on the completion of the first
cohort of dogs in a clinical study, which examined the benefit and
tolerability of an intra-articular injection of a collagen-elastin
biomaterial (i.e. Spryng™ with OsteoCuhsion™ Technology) into the
stifle joint of dogs with suspected cruciate ligament rupture.
“We were pleased to have Dr. Kleeman present the
Spryng clinical study first cohort results at the VOS annual
conference as these data demonstrated initial tolerability and
further supports our representations regarding the efficacy of this
product as a viable option to assist in the management of lamenes
in companion animals,” said John Lai, Chief Executive Officer of
PetVivo Holdings, Inc.
Spryng is an injectable veterinary medical
device comprised of millions of micronized extracellular matrix
particles, which are derived from natural components, including
collagen and elastin. OsteoCushion Technology provides both
reinforcing natural joint support to augment and/or reinforce
missing and damaged cartilage, as well as delivers natural
scaffolding to help address tissue defects. These attributes offer
a great solution to manage lameness and joint afflictions, such as
osteoarthritis, for companion animals in a simple in-clinic
administration.
The dogs enrolled in this study had been
diagnosed with a cranial cruciate ligament injury (similar to an
ACL tear in humans). The primary endpoint of the study was to
demonstrate whether there was a significant reduction in pain after
injection, as measured by the modified Glasgow Composite Pain
Scale. The response rate among the 22 dogs in cohort 1 was 64%,
with the responder group showing a mean improvement in their pain
scores of 51%. There were also significant improvements in all of
the other secondary clinical variables throughout the study period
(lameness, osteoarthritis scoring). In summary, this study
demonstrates that Spryng™ may be a viable alternative for medical
management of dogs with a CCL injury. To view the abstract of the
clinical study presented at the VOS annual conference please visit
the following:
https://rabbit-lute-apwt.squarespace.com/s/Spryng-canine-VOS-abstract-SECS-1-0323.pdf.
About Ethos Veterinary
Health
Ethos Veterinary Health is a unique and
impactful science-focused animal health company with an emphasis on
collaboration, evidence-based decision making, a commitment to the
veterinary ethos, and cultivation of passion for what we do. The
Company operates 18 hospitals across the United States, with over
400 Doctors of Veterinary Medicine, providing advanced medical care
for pets. Our approach includes a focus on transformative science,
continuous learning and growth for team members and collaboration.
For more information, visit www.ethosvet.com.
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injection for the management of lameness and other
joint related afflictions, including osteoarthritis, in dogs and
horses, is currently available for commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/
CONTACT:John Lai, CEOPetVivo Holdings,
Inc.Email: info1@petvivo.com(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024